Intervacc AB (FRA:2E9) Return-on-Tangible-Equity: -60.05% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2E9 Intervacc AB FRA:2E9
63 GF Score
Price €0.09
GF Value €0.08
! 5 Warning Signs
View Full Analysis

What is Intervacc AB Return-on-Tangible-Equity?

Intervacc AB FRA:2E9 -2.57% 63 Return-on-Tangible-Equity is -60.05% as of Mar. 2026. GuruFocus rates FRA:2E9 with a GF Score™ of 63/100 and a GF Value™ of €0.08. The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Intervacc AB ranks worse than 54.13% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Intervacc AB's annualized net income for the quarter that ended in Mar. 2026 was €-8.07 Mil. Intervacc AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €13.44 Mil. Therefore, Intervacc AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -60.05%.

The historical rank and industry rank for Intervacc AB's Return-on-Tangible-Equity or its related term are showing as below:

FRA:2E9' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -137   Med: -61.01   Max: -20.97
Current: -50.41

During the past 12 years, Intervacc AB's highest Return-on-Tangible-Equity was -20.97%. The lowest was -137.00%. And the median was -61.01%.

FRA:2E9's Return-on-Tangible-Equity is ranked worse than
54.13% of 1199 companies
in the Biotechnology industry
Industry Median: -42.21 vs FRA:2E9: -50.41

Intervacc AB  (FRA:2E9) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Intervacc AB Return-on-Tangible-Equity Related Terms


Intervacc AB Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Intervacc AB's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intervacc AB Return-on-Tangible-Equity Chart

Intervacc AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.85 -64.27 -128.79 -134.10 -89.57

Intervacc AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.70 -34.72 -29.81 -83.43 -60.05

FRA:2E9 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, Intervacc AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intervacc AB Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intervacc AB's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Intervacc AB's Return-on-Tangible-Equity falls into.


FRA:2E9
63GF Score
Intervacc AB FRA:2E9
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intervacc AB Return-on-Tangible-Equity Calculation

Intervacc AB's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-7.426/( (2.266+14.316 )/ 2 )
=-7.426/8.291
=-89.57 %

Intervacc AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-8.068/( (14.316+12.554)/ 2 )
=-8.068/13.435
=-60.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -60.05% mean?
Intervacc AB (FRA:2E9) has a Return-on-Tangible-Equity of -60.05% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Intervacc AB and its competitors. According to the industry distribution chart, Intervacc AB ranks #649 out of 1199 companies in the Biotechnology industry, placing it in the top 54.1%.
Is Intervacc AB's Return-on-Tangible-Equity too high?
Intervacc AB's current Return-on-Tangible-Equity is -60.05%. Based on the distribution chart, Intervacc AB ranks #649 out of 1199 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #649 out of 1199 companies for Return-on-Tangible-Equity. This places Intervacc AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Intervacc AB and its competitors. Intervacc AB's current Return-on-Tangible-Equity is -60.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Return-on-Tangible-Equity of -60.05%. The stock's GF Value™ is €0.08, compared to a current price of €0.09 — trading 18.6% above its estimated fair value. The current Return-on-Tangible-Equity is -60.05%. Intervacc AB's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Return-on-Tangible-Equity is -60.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intervacc AB (FRA:2E9) Overvalued in 2026?

Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued. The current stock price of €0.09 is trading 18.6% above its estimated GF Value™ of €0.08.

Key valuation signals for FRA:2E9:

  • Return-on-Tangible-Equity: -60.05%
  • GF Value™: €0.08 vs. price of €0.09 (18.6% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intervacc AB Business Description

Other Exchanges IVACC:Sweden
Address Vastertorpsvagen 135, Hagersten, Stockholm, SWE, S-129 44
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score

Get the complete analysis for FRA:2E9

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price
€0.08
GF Value